respectively. The adverse reactions leading to discontinuation in 2% or more of patients on SEROQUEL and at a greater incidence than placebo were somnolence (4.1% vs. 1.1%) and fatigue (2.1% vs. 0).
The results of a large retrospective cohort study appear to indicate that atypical antipsychotic agents (e.g., clozapine, olanzapine, risperidone, this drug) increase the risk of venous thromboembolism in elderly patients; however, these events seem to be rare....
In placebo-controlled trials with risperidone, aripiprazole, and olanzapine in elderly subjects with dementia, there was a higher incidence of cerebrovascular adverse reactions (cerebrovascular accidents and transient ischemic attacks), including fatalities, compared to placebo-treated subjects. Quetiapine exten...
In placebo-controlled trials with risperidone, aripiprazole, and olanzapine in elderly subjects with dementia, there was a higher incidence of cerebrovascular adverse reactions (cerebrovascular accidents and transient ischemic attacks) including fatalities compared to placebo-treated subjects. SEROQUEL is not ...
Quetiapine (mean dosage 62.5 mg/day) was also an effective alternative for improving psychosis in 29 patients unresponsive to or who could not tolerate other atypical antipsychotics (clozapine, risperidone or olanzapine), or those who were noncompliant with blood monitoring. A statistically significant ...
Interim results suggest similar efficacy for quetiapine (600 mg/day), olanzapine (15 mg/day) and risperidone (5 mg/day) in a small, randomised, rater-blinded trial. Furthermore, improvements in overall psychopathology and the positive and negative symptoms of schizophrenia were similar with quetiap...
Receptors Involved in Mental Disorders and the Use of Clozapine, Chlorpromazine, Olanzapine, and Aripiprazole to Treat Mental Disorders. Pharmaceuticals 2023, 16, 603. [Google Scholar] [CrossRef] DeVane, C.L.; Nemeroff, C.B. Clinical pharmacokinetics of quetiapine: An atypical antipsychotic. Clin...
to adverse reactions for quetiapine-treated and placebo-treated patients was 11.4% and 4.4%, respectively. The adverse reactions leading to discontinuation in 2% or more of patients on SEROQUEL and at a greater incidence than placebo were somnolence (4.1% vs. 1.1%) and fatigue (2.1% vs. 0...
to adverse reactions for quetiapine-treated and placebo-treated patients was 11.4% and 4.4%, respectively. The adverse reactions leading to discontinuation in 2% or more of patients on SEROQUEL and at a greater incidence than placebo were somnolence (4.1% vs. 1.1%) and fatigue (2.1% vs. 0...
of the disease [1]. In the majority of patients, lack of insight occurs even in the early stages of the disease and represents an important predictive factor for the occurrence of neuropsychiatric symptoms, including apathy, agitation, irritability, psychosis, or behavioral symptoms in general [2...